# Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

> **NCT00558311** · PHASE3 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 1157 (actual)

## Conditions studied

- Aneurysmal Subarachnoid Hemorrhage

## Interventions

- **DRUG:** Clazosentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00558311
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-14
- **Primary completion:** 2010-06-15
- **Final completion:** 2010-07-13
- **Target enrollment:** 1157 (ACTUAL)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558311, "Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00558311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*